A study to assess the effect of 3 different doses of LIK066 in patients with type 2 diabetes and heart failure, compared to the effect of placebo or empagliflozin

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-003084-19

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the dose-response relationship of three dose regimens of LIK066 as measured by the change from baseline in NT-proBNP relative to placebo after 12 weeks of treatment in T2DM patients with HF


Critère d'inclusion

  • Patients with type 2 diabetes mellitus and heart failure

Liens